The Role of IgE in Upper and Lower Airway Disease: More Than Just Allergy!

Abstract

Immunoglobulin E (IgE) is a well-known key factor in allergic airway disease; however, its central role in non-allergic airway inflammation is often underestimated. In some airway diseases, IgE is produced as a result of allergic sensitization. However, in others, IgE production occurs despite the lack of a specific allergen. Although multiple pathways contribute to the production of IgE in airway disease, it is its activity in mediating the inflammatory response that is associated with disease. Therefore, an understanding of IgE as the unifying component of upper and lower airway diseases has important implications for both diagnosis and treatment. Understanding the role of IgE in each upper and lower airway disease highlights its potential utility as a diagnostic marker and therapeutic target. Further classification of these diseases by whether they are IgE mediated or non–IgE mediated, rather than by the existence of an underlying allergic component, accounts for both systemic and localized IgE activity. Improvements in diagnostic methodologies and standardization of clinical practices with this classification in mind can help identify patients with IgE-mediated diseases. In doing so, this group of patients can receive optimal care through targeted anti-IgE therapeutics, which have already demonstrated efficacy across numerous IgE-mediated upper and lower airway diseases.

Immune repertoire sequencing reveals an abnormal adaptive immune system in COVID‐19 survivors

“…Only one recent report pointed out that more severe COVID‐19 patients had higher levels of IgE. 32 In addition, IgE is a key player in airway disease, 33 which is unlikely to be associated with SARS‐CoV‐2‐specific reactions but a consequence of airway inflammation.…”

Resveratrol Attenuates Mast Cell Mediated Allergic Reactions: Potential for Use as a Nutraceutical in Allergic Diseases?

“…[ 53 ] Once produced, local IgE acts on the FcεRI receptors of tissue‐resident MCs and basophils which results in the release of histamine or leukotrienes leading to edema, vasodilation, and bronchoconstriction. [ 54 ] Adult AR patients treated with RESV (100 µL per spray) showed a reduction in nasal symptoms compared to the placebo group. In this context, this polyphenol led to a decrease of IgE (≈40%), IL‐4 (≈30%), TNF‐α (≈10%), and eosinophil levels (≈80%) in the blood of the participants.…”

“…[53] Diseases of the upper respiratory system are characterized by a common mechanism in the type 2 inflammatory pathway mediated by several inflammatory cells, such as eosinophils, mast cells, basophils, Th2 cells, or IgE-producing B cells, which release several mediators, chemokines, and cytokines. [53,54] In this context, MC mediators are released upon IgE-dependent mechanism in AR, but they can also induce IgE generation in B cells. [53] Once produced, local IgE acts on the Fc𝜖RI receptors of tissue-resident MCs and basophils which results in the release of histamine or leukotrienes leading to edema, vasodilation, and bronchoconstriction.…”

The Role of Omalizumab in NSAID-Exacerbated Respiratory Disease: A Narrative Review

“…N-ERD is a complex disease involving many types of inflammatory cells, cytokines, and lipid mediators (Figure 1). 2,[5][6][7][8] Some of the most widely discussed pathogenic mechanisms of N-ERD focus on the role of arachidonic acid metabolism, cysteinyl leukotrienes (CysLTs), and prostaglandin D2 (PGD2), as well as the role of mast cells, platelets, and other components of the innate immune system.…”